Series A Biotech companies in New York

Evvy is unlocking precision women’s healthcare through novel, overlooked female biomarkers — starting with the vaginal microbiome. Backed by leading healthcare investors such as General Catalyst, Left Lane Capital, and LabCorp, the Evvy team includes leading OB/GYNs and vaginal microbiome researchers with decades of experience at organizations like UCSF, Stanford, Harvard, Cleveland Clinic, and more. Evvy is one of the fastest growing women’s health companies in the US — enabling us to deliver innovative, high quality care while scaling novel R&D to unlock a new, data-driven future in women’s health.Evvy’s Vaginal Health Test is the first at-home vaginal microbiome test to use metagenomic sequencing to tell you what’s up down there, why it matters, and what you can do about it. Evvy’s larger platform is the first vaginal healthcare service to bring together state-of-the-art testing, precision clinical care, and 1:1 coaching to give women and people with vaginas the care they deserve. Through this platform, Evvy is building real-world datasets that can transform our understanding of complex female health conditions. Imagine a world where female health is finally understood: where risks are detected early and precisely; conditions are defined with specificity and nuance; and diseases are treated with personalization and care. That’s the world that Evvy is pioneering.

• Series A
• 61 employees
• Founded 2020

TandemAI is an advanced technology company dedicated to reinventing drug discovery infrastructure. The company integrates proprietary AI-driven, high-performance computation with its efficient, large-scale in-house wet lab operations to deliver a turnkey drug discovery solution. TandemAI has built its networked platform from the ground up in the U.S. and China to increase the speed of drug discovery and deliver cost-effective opportunities to its partners and to the global scientific community.

• Series A
• 51 employees
• Founded 2021

Accelerating scientific research and discoveries through the automation of histology and digital pathology solutions.Enhancing the human condition is what fuels our passion. Our services empower life science companies and researchers to introduce impactful breakthroughs and therapies to market with greater speed and precision than ever before. Our leading capabilities across histology, immunostaining, slide archiving/digitization services, pathology consultation, and image analysis consultation enable our customers to concentrate on the key questions to accelerate the processes of discovery, development, and delivery.We are much more than your average histology service provider. Our laboratory information system, PathologyMapTM, hosts one of the largest collections of preclinical data in the world and allows researchers the ability to instantly view, manage, and share their digital slides in seconds.HistoWiz emerged in 2013 as a valuable resource for scientific researchers seeking faster turnaround times than traditional histology cores could offer. This dedication to providing rapid results remains a cornerstone of our service, prompting customers to return to us time and time again.Quality first.Quality is behind everything that we do. From receiving your slides, to the quality of our images, through to our consultation teams, we adhere to the highest standards of quality and compliance.We support both GLP and non-GLP studies of all types and sizes. Our quality management system for GLP ensures FDA and EPA regulatory adherence.

• Series A
• 48 employees
• Founded 2012

Founded by Kian Sadeghi in 2021, Nucleus Genomics is a fertility startup that helps people have their bestbaby. It offers a complete end-to-end family planning platform, spanning advanced preconception testing,embryo analysis and full-service IVF care. With the goal of building generational health, Nucleus has raisedover $32 million to date with investors including Founders Fund, Seven Seven Six, and Samsung Next.

• Series A
• 43 employees
• Founded 2021

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.

• Series A
• 41 employees
• Founded 2019